204 related articles for article (PubMed ID: 27103745)
1. TNFRSF14 aberrations in follicular lymphoma increase clinically significant allogeneic T-cell responses.
Kotsiou E; Okosun J; Besley C; Iqbal S; Matthews J; Fitzgibbon J; Gribben JG; Davies JK
Blood; 2016 Jul; 128(1):72-81. PubMed ID: 27103745
[TBL] [Abstract][Full Text] [Related]
2. High TNFRSF14 and low BTLA are associated with poor prognosis in Follicular Lymphoma and in Diffuse Large B-cell Lymphoma transformation.
Carreras J; Lopez-Guillermo A; Kikuti YY; Itoh J; Masashi M; Ikoma H; Tomita S; Hiraiwa S; Hamoudi R; Rosenwald A; Leich E; Martinez A; Roncador G; Villamor N; Colomo L; Perez P; Tsuji NM; Campo E; Nakamura N
J Clin Exp Hematop; 2019; 59(1):1-16. PubMed ID: 30918139
[TBL] [Abstract][Full Text] [Related]
3. Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells.
Boice M; Salloum D; Mourcin F; Sanghvi V; Amin R; Oricchio E; Jiang M; Mottok A; Denis-Lagache N; Ciriello G; Tam W; Teruya-Feldstein J; de Stanchina E; Chan WC; Malek SN; Ennishi D; Brentjens RJ; Gascoyne RD; Cogné M; Tarte K; Wendel HG
Cell; 2016 Oct; 167(2):405-418.e13. PubMed ID: 27693350
[TBL] [Abstract][Full Text] [Related]
4. Concomitant 1p36 deletion and TNFRSF14 mutations in primary cutaneous follicle center lymphoma frequently expressing high levels of EZH2 protein.
Gángó A; Bátai B; Varga M; Kapczár D; Papp G; Marschalkó M; Kuroli E; Schneider T; Csomor J; Matolcsy A; Bödör C; Szepesi Á
Virchows Arch; 2018 Oct; 473(4):453-462. PubMed ID: 29858685
[TBL] [Abstract][Full Text] [Related]
5. Genome-wide analysis of pediatric-type follicular lymphoma reveals low genetic complexity and recurrent alterations of TNFRSF14 gene.
Schmidt J; Gong S; Marafioti T; Mankel B; Gonzalez-Farre B; Balagué O; Mozos A; Cabeçadas J; van der Walt J; Hoehn D; Rosenwald A; Ott G; Dojcinov S; Egan C; Nadeu F; Ramis-Zaldívar JE; Clot G; Bárcena C; Pérez-Alonso V; Endris V; Penzel R; Lome-Maldonado C; Bonzheim I; Fend F; Campo E; Jaffe ES; Salaverria I; Quintanilla-Martinez L
Blood; 2016 Aug; 128(8):1101-11. PubMed ID: 27257180
[TBL] [Abstract][Full Text] [Related]
6. B-Lymphoblastic Lymphomas Evolving from Follicular Lymphomas Co-Express Surrogate Light Chains and Mutated Gamma Heavy Chains.
Slot LM; Hoogeboom R; Smit LA; Wormhoudt TA; Biemond BJ; Oud ME; Schilder-Tol EJ; Mulder AB; Jongejan A; van Kampen AH; Kluin PM; Guikema JE; Bende RJ; van Noesel CJ
Am J Pathol; 2016 Dec; 186(12):3273-3284. PubMed ID: 27750045
[TBL] [Abstract][Full Text] [Related]
7. A herpesvirus entry mediator mutein with selective agonist action for the inhibitory receptor B and T lymphocyte attenuator.
Šedý JR; Balmert MO; Ware BC; Smith W; Nemčovičova I; Norris PS; Miller BR; Aivazian D; Ware CF
J Biol Chem; 2017 Dec; 292(51):21060-21070. PubMed ID: 29061848
[TBL] [Abstract][Full Text] [Related]
8. Recurrent mutations in genes involved in nuclear factor-κB signalling in nodal marginal zone lymphoma-diagnostic and therapeutic implications.
van den Brand M; Rijntjes J; Hebeda KM; Menting L; Bregitha CV; Stevens WB; van der Velden WJ; Tops BB; van Krieken JH; Groenen PJ
Histopathology; 2017 Jan; 70(2):174-184. PubMed ID: 27297871
[TBL] [Abstract][Full Text] [Related]
9. Targeting of B and T lymphocyte associated (BTLA) prevents graft-versus-host disease without global immunosuppression.
Albring JC; Sandau MM; Rapaport AS; Edelson BT; Satpathy A; Mashayekhi M; Lathrop SK; Hsieh CS; Stelljes M; Colonna M; Murphy TL; Murphy KM
J Exp Med; 2010 Nov; 207(12):2551-9. PubMed ID: 21078889
[TBL] [Abstract][Full Text] [Related]
10. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
11. Selective blockade of herpesvirus entry mediator-B and T lymphocyte attenuator pathway ameliorates acute graft-versus-host reaction.
del Rio ML; Jones ND; Buhler L; Norris P; Shintani Y; Ware CF; Rodriguez-Barbosa JI
J Immunol; 2012 May; 188(10):4885-96. PubMed ID: 22490863
[TBL] [Abstract][Full Text] [Related]
12. Molecular cloning and characterization of TNFSF14 (LIGHT) and its receptor TNFRSF14 (HVEM) in guinea pig (Cavia porcellus).
Li C; Chen S; Song J; Liu H; Gu W; Ai H; Zhao B; Zhang S
Gene; 2013 Sep; 526(2):374-84. PubMed ID: 23732292
[TBL] [Abstract][Full Text] [Related]
13. Acquired TNFRSF14 mutations in follicular lymphoma are associated with worse prognosis.
Cheung KJ; Johnson NA; Affleck JG; Severson T; Steidl C; Ben-Neriah S; Schein J; Morin RD; Moore R; Shah SP; Qian H; Paul JE; Telenius A; Relander T; Lam W; Savage K; Connors JM; Brown C; Marra MA; Gascoyne RD; Horsman DE
Cancer Res; 2010 Nov; 70(22):9166-74. PubMed ID: 20884631
[TBL] [Abstract][Full Text] [Related]
14. Involvement of the CD27-CD70 co-stimulatory pathway in allogeneic T-cell response to follicular lymphoma cells.
Schmitter D; Bolliger U; Hallek M; Pichert G
Br J Haematol; 1999 Jul; 106(1):64-70. PubMed ID: 10444164
[TBL] [Abstract][Full Text] [Related]
15. Recurrent loss of heterozygosity in 1p36 associated with TNFRSF14 mutations in IRF4 translocation negative pediatric follicular lymphomas.
Martin-Guerrero I; Salaverria I; Burkhardt B; Szczepanowski M; Baudis M; Bens S; de Leval L; Garcia-Orad A; Horn H; Lisfeld J; Pellissery S; Klapper W; Oschlies I; Siebert R
Haematologica; 2013 Aug; 98(8):1237-41. PubMed ID: 23445872
[TBL] [Abstract][Full Text] [Related]
16. Mutations of
Schmidt J; Ramis-Zaldivar JE; Nadeu F; Gonzalez-Farre B; Navarro A; Egan C; Montes-Mojarro IA; Marafioti T; Cabeçadas J; van der Walt J; Dojcinov S; Rosenwald A; Ott G; Bonzheim I; Fend F; Campo E; Jaffe ES; Salaverria I; Quintanilla-Martinez L
Blood; 2017 Jul; 130(3):323-327. PubMed ID: 28533310
[TBL] [Abstract][Full Text] [Related]
17. Induction of alloantigen-specific anergy in human peripheral blood mononuclear cells by alloantigen stimulation with co-stimulatory signal blockade.
Davies JK; Barbon CM; Voskertchian AR; Nadler LM; Guinan EC
J Vis Exp; 2011 Mar; (49):. PubMed ID: 21445041
[TBL] [Abstract][Full Text] [Related]
18. Graft Engineering and Adoptive Immunotherapy: New Approaches to Promote Immune Tolerance After Hematopoietic Stem Cell Transplantation.
Bertaina A; Roncarolo MG
Front Immunol; 2019; 10():1342. PubMed ID: 31354695
[TBL] [Abstract][Full Text] [Related]
19. BEAM-Campath Allogeneic Stem Cell Transplant for Patients with Relapsed/Refractory Lymphoma: High Incidence of Long-Term Mixed Donor-Recipient Chimerism and the Response to Donor Lymphocyte Infusions.
Burney C; Wadhera K; Breslin P; Pearce R; Wells M; Alajangi R; Protheroe R; Marks DI; Griffin J; Robinson S
Biol Blood Marrow Transplant; 2020 Dec; 26(12):2271-2278. PubMed ID: 32890747
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR.
Sureda A; Zhang MJ; Dreger P; Carreras J; Fenske T; Finel H; Schouten H; Montoto S; Robinson S; Smith SM; Boumedil A; Hamadani M; Pasquini MC
Cancer; 2018 Apr; 124(8):1733-1742. PubMed ID: 29424927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
